Ocugen宣布Stargardt病治疗药物Ocu410st的2/3期关键验证试验提前完成给药

美股速递
Apr 01

Ocugen公司宣布,针对Stargardt病的基因治疗药物Ocu410st,其关键性2/3期验证试验的给药阶段已提前完成。这一进展标志着该疗法在临床开发中迈出了重要一步,为后续疗效和安全性评估奠定了基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10